These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 30526033)
21. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445 [TBL] [Abstract][Full Text] [Related]
22. Cyclic dinucleotides modulate induced type I IFN responses in innate immune cells by degradation of STING. Rueckert C; Rand U; Roy U; Kasmapour B; Strowig T; Guzmán CA FASEB J; 2017 Jul; 31(7):3107-3115. PubMed ID: 28396343 [TBL] [Abstract][Full Text] [Related]
23. Effects of STING stimulation on macrophages: STING agonists polarize into "classically" or "alternatively" activated macrophages? Ohkuri T; Kosaka A; Nagato T; Kobayashi H Hum Vaccin Immunother; 2018 Feb; 14(2):285-287. PubMed ID: 29064738 [TBL] [Abstract][Full Text] [Related]
24. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051 [TBL] [Abstract][Full Text] [Related]
25. Cyclic Dinucleotides Inhibit Osteoclast Differentiation Through STING-Mediated Interferon-β Signaling. Kwon Y; Park OJ; Kim J; Cho JH; Yun CH; Han SH J Bone Miner Res; 2019 Jul; 34(7):1366-1375. PubMed ID: 30779854 [TBL] [Abstract][Full Text] [Related]
26. STING-mediated DNA sensing in cancer immunotherapy. Zhou X; Jiang Z Sci China Life Sci; 2017 Jun; 60(6):563-574. PubMed ID: 28639100 [TBL] [Abstract][Full Text] [Related]
27. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response. Li T; Cheng H; Yuan H; Xu Q; Shu C; Zhang Y; Xu P; Tan J; Rui Y; Li P; Tan X Sci Rep; 2016 Jan; 6():19049. PubMed ID: 26754564 [TBL] [Abstract][Full Text] [Related]
28. STING pathway agonism as a cancer therapeutic. Flood BA; Higgs EF; Li S; Luke JJ; Gajewski TF Immunol Rev; 2019 Jul; 290(1):24-38. PubMed ID: 31355488 [TBL] [Abstract][Full Text] [Related]
29. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082 [TBL] [Abstract][Full Text] [Related]
30. Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations. Novotná B; Vaneková L; Zavřel M; Buděšínský M; Dejmek M; Smola M; Gutten O; Tehrani ZA; Pimková Polidarová M; Brázdová A; Liboska R; Štěpánek I; Vavřina Z; Jandušík T; Nencka R; Rulíšek L; Bouřa E; Brynda J; Páv O; Birkuš G J Med Chem; 2019 Dec; 62(23):10676-10690. PubMed ID: 31715099 [TBL] [Abstract][Full Text] [Related]
31. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Corrales L; Glickman LH; McWhirter SM; Kanne DB; Sivick KE; Katibah GE; Woo SR; Lemmens E; Banda T; Leong JJ; Metchette K; Dubensky TW; Gajewski TF Cell Rep; 2015 May; 11(7):1018-30. PubMed ID: 25959818 [TBL] [Abstract][Full Text] [Related]
32. Detection of Cyclic Dinucleotides by STING. Du XX; Su XD Methods Mol Biol; 2017; 1657():59-69. PubMed ID: 28889286 [TBL] [Abstract][Full Text] [Related]
33. STING signaling in tumorigenesis and cancer therapy: A friend or foe? He L; Xiao X; Yang X; Zhang Z; Wu L; Liu Z Cancer Lett; 2017 Aug; 402():203-212. PubMed ID: 28602976 [TBL] [Abstract][Full Text] [Related]
34. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378 [TBL] [Abstract][Full Text] [Related]
35. Assessment of Th1/Th2 Bias of STING Agonists Coated on Microneedles for Possible Use in Skin Allergen Immunotherapy. Shakya AK; Lee CH; Uddin MJ; Gill HS Mol Pharm; 2018 Nov; 15(11):5437-5443. PubMed ID: 30299105 [TBL] [Abstract][Full Text] [Related]
36. [Cytosolic DNA sensing by the cGAS-STING pathway in cancer]. Chanut R; Petrilli V Med Sci (Paris); 2019; 35(6-7):527-534. PubMed ID: 31274082 [TBL] [Abstract][Full Text] [Related]
37. STING signaling: a key to therapeutic tumor immunity. Foote JB; Emens LA Immunotherapy; 2018 Jul; 10(9):729-731. PubMed ID: 30008260 [No Abstract] [Full Text] [Related]